Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Meredith M ReganCharlene M MantiaLillian WernerAhmad A TarhiniJames LarkinF Stephen HodiJedd WolchokMichael A PostowBrian StwalleyAndriy MoshykCorey RitchingsSandra ReWim van DijckDavid F McDermottMichael B AtkinsPublished in: Journal for immunotherapy of cancer (2022)
Along with improved long-term OS with the nivolumab-containing regimens versus ipilimumab, TFS without toxicity was sustained with nivolumab plus ipilimumab versus either monotherapy, demonstrating larger between-group differences with extended follow-up.